Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants

November 17, 2015 updated by: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Pancreatic Cancer Serum and Peripheral Blood Lymphocyte Repository

RATIONALE: Collecting and storing samples of blood from patients with cancer and healthy participants to test in the laboratory may help the study of cancer in the future.

PURPOSE: This study is collecting and storing samples of blood from patients with pancreatic cancer and healthy participants.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

  • Establish a central pancreatic cancer specimen (including serum and peripheral blood lymphocytes) repository to serve as a resource for current or future scientific studies.
  • Utilize the clinical database to perform clinicopathologic correlation with the results of those studies.
  • Test new hypotheses as they emerge.

OUTLINE: This is a prospective study.

Blood is collected from patients with pancreatic cancer at baseline and then every 3-6 months for up to 2 years. All other participants have blood collected at baseline and complete questionnaires at baseline and then every 3-6 months for up to 2 years. Serum and peripheral blood lymphocytes obtained from the blood samples are frozen and stored.

PROJECTED ACCRUAL: A total of 200 patients and 200 other participants will be accrued for this study.

Study Type

Observational

Enrollment (Actual)

88

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 120 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The three cohorts are: 1) Healthy individuals, 2) At risk individuals and 3) Cancer patients.

Description

DISEASE CHARACTERISTICS:

  • Meets 1 of the following criteria:

    • Histologically confirmed pancreatic malignant neoplasm
    • Serologically or image-confirmed diagnosis of pancreatitis or nonmalignant pancreatic disease

    • Healthy, at-risk participant meeting the following criteria:

      • Smoker, diabetic, and/or has a family history of pancreatic cancer
    • Healthy participant (no history of cancer)

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy individuals
Other: This is a non-intervention study for all groups.
This is a non-intervention study.
Other: study of socioeconomic and demographic variables
Non-intervention study.
At risk individuals
Other: This is a non-intervention study for all groups.
This is a non-intervention study.
Other: study of socioeconomic and demographic variables
Non-intervention study.
Cancer patients
Other: This is a non-intervention study for all groups.
This is a non-intervention study.
Other: study of socioeconomic and demographic variables
Non-intervention study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Establishment of a central pancreatic cancer specimen repository
Time Frame: No time frame
No time frame
Utilization of the clinical database to perform clinicopathologic correlation with the results of current or future scientific studies
Time Frame: No time frame
No time frame
Test new hypotheses as they emerge
Time Frame: No time frame
No time frame

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

National Cancer Institute (NCI)

Investigators

  • Study Chair: Daniel A. Laheru, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2005

Primary Completion (Actual)

June 1, 2011

Study Completion (Actual)

June 1, 2011

Study Registration Dates

First Submitted

May 9, 2009

First Submitted That Met QC Criteria

May 9, 2009

First Posted (Estimate)

May 12, 2009

Study Record Updates

Last Update Posted (Estimate)

November 20, 2015

Last Update Submitted That Met QC Criteria

November 17, 2015

Last Verified

November 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • JHOC-J0533 CDR0000452792
  • P30CA006973 (U.S. NIH Grant/Contract)
  • JHOC-J0533
  • JHOC-05042601

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatic Cancer

Clinical Trials on This is a non-intervention study for all groups.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe